These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
71 related items for PubMed ID: 3550785
1. Beta cell function in insulin-treated non-insulin-dependent diabetic patients. Ramachandran A, Snehalatha C, Mohan V, Rao CA, Viswanathan M. Pancreas; 1986; 1(5):411-4. PubMed ID: 3550785 [Abstract] [Full Text] [Related]
2. Beta cell function in long term NIDDM (type 2) patients and its relation to treatment. Snehalatha C, Ramachandran A, Mohan V, Timothy H, Viswanathan M. Horm Metab Res; 1986 Jun; 18(6):391-4. PubMed ID: 3525362 [Abstract] [Full Text] [Related]
3. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306 [Abstract] [Full Text] [Related]
4. Pancreatic beta cell response in insulin treated NIDDM patients limitations of a random C-peptide measurement. Snehalatha C, Ramachandran A, Mohan V, Viswanathan M. Diabete Metab; 1987 Feb; 13(1):27-30. PubMed ID: 3552773 [Abstract] [Full Text] [Related]
5. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release. Pontiroli AE, Calderara A, Maffi P, Bonisolli L, Carenini A, Piatti PM, Monti LD, Gallus G, Pozza G, Illeni MT. Diabete Metab; 1989 Feb; 15(2):79-84. PubMed ID: 2661281 [Abstract] [Full Text] [Related]
6. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy. Greco AV, Caputo S, Bertoli A, Ghirlanda G. Horm Metab Res; 1992 Jun; 24(6):280-3. PubMed ID: 1634193 [Abstract] [Full Text] [Related]
7. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. Kudolo GB. J Clin Pharmacol; 2001 Jun; 41(6):600-11. PubMed ID: 11402628 [Abstract] [Full Text] [Related]
8. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Chen KW, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, Fujimoto WY. Diabetes Care; 1995 Jun; 18(6):747-53. PubMed ID: 7555498 [Abstract] [Full Text] [Related]
9. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects. Kawamori R, Bando K, Yamasaki Y, Kubota M, Watarai T, Iwama N, Shichiri M, Kamada T. Diabetes Care; 1989 Jun; 12(10):680-5. PubMed ID: 2515048 [Abstract] [Full Text] [Related]
10. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Clark HE, Matthews DR. Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981 [Abstract] [Full Text] [Related]
11. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. van der Wal PS, Draeger KE, van Iperen AM, Martini C, Aarsen M, Heine RJ. Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393 [Abstract] [Full Text] [Related]
12. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Savage S, Estacio RO, Jeffers B, Schrier RW. Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587 [Abstract] [Full Text] [Related]
13. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Zavala AV, Fabiano de Bruno LE, Cardoso AI, Mota AH, Capucchio M, Poskus E, Fainboim L, Basabe JC. Diabetologia; 1992 Dec; 35(12):1159-64. PubMed ID: 1478368 [Abstract] [Full Text] [Related]
14. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Polonsky KS. Diabetes; 1995 Jun; 44(6):705-17. PubMed ID: 7789637 [Abstract] [Full Text] [Related]
15. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B. Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326 [Abstract] [Full Text] [Related]
16. A prospective study of glucose profiles, insulin antibody levels and beta cells secretory patterns in non-obese Ugandan diabetic subjects. Otim MA. East Afr Med J; 1988 Jan; 65(1):8-15. PubMed ID: 3046922 [No Abstract] [Full Text] [Related]
17. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E. Acta Endocrinol (Copenh); 1988 Jul; 118(3):365-73. PubMed ID: 3293339 [Abstract] [Full Text] [Related]
18. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC. Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556 [Abstract] [Full Text] [Related]
19. C-peptide response to meal challenge in nondiabetic and diabetic adults living in Wadena, Minnesota. Bushhouse SA, Goetz FC, Jacobs DR, Bender AP, French LR, Oestreich PG, Geisser MS. Diabetes Care; 1992 Oct; 15(10):1335-47. PubMed ID: 1425099 [Abstract] [Full Text] [Related]
20. Impact of family history of diabetes on the assessment of beta-cell function. Alford FP, Henriksen JE, Rantzau C, Vaag A, Hew LF, Ward GM, Beck-Nielsen H. Metabolism; 1998 May; 47(5):522-8. PubMed ID: 9591741 [Abstract] [Full Text] [Related] Page: [Next] [New Search]